|
CLINICAL TRIAL DOCUMENTS |
• |
Centperazine (Anti-filarial):
Summary of Phase I clinical pharmacological
data on (3 ethyl 8 methyl 1, 3,
8 triazo bicyclo (4, 10) decan 2
one, Centperazine .Vol. 2, 1976. |
• |
Centazolone (Tranquillo-Sedative):
Summary of Phase II clinical pharmacological
data on 3- amino-benzo-(6, 7)-quinozoline-4-one,
Centazolone .Vol. 3, 1976. |
• |
Centbutindole (Neuroleptic): Summary
of Phase I clinical pharmacological
data on 2-r- p-fluorobenzoyl propyl
1, 2, 3, 4, 6, 7, 12, 12A, octahydropyrazino
(2', 1': 6, 1 pyrido (3, 4) indole,
Centbutindole .Vol. 3, 1977. |
• |
Centpropazine (Anti-depressant):
Summary of Phase I clinical pharmacology
data on 1(p- propionyl phenoxy) 3-(N-phenyl
piperazinyl) propan-2-OL, Centpropazine.Vol.2,
1977. |
• |
Gugulipid (Hypolipidaemic): Summary
of clinical pharmacology data on Gugulipid
(Phase I study) .Vol.2, (1978). |
• |
Gugulipid (Hypolipidaemic): Summary
of clinical pharmacology data on Gugulipid
(Phase II study) .Vol. 3, (1981).
|
• |
Mefloquine (Anti-malarial): Summary
of Phase I clinical pharmacology data
on mefloquine.Vol.2, (1983). |
• |
Mefloquine Combination (Anti-malarial):
Summary of preclinical, toxicological,
pharmacological and clinical pharmacological
data on Mefloquine, Pyrimethamine
and Sulphadoxine combination (1984). |
• |
Centbutindole (Neuroleptic): Phase
III clinical data and summary of preclinical,
Phase I & II clinical data (1986). |
• |
Gugulipid (Hypolipidaemic): Phase
III clinical data and summary of
preclinical & Phase I &
II clinical data revised (1986). |
• |
Chandonium Iodide (Neuromuscular
blocking agent): Phase I/II clinical
data & preclinical data (1987). |
• |
Centchroman (Anti-breast cancer):
Summary of preclinical data, plan
and results of Phase II trial and
plan for Phase III clinical trial
(1988). |
• |
Centpropazine (Anti-depressant):
Phase II clinical data (1989). |
• |
ab Arteether (Blood schizontocidal
anti-malarial): Summary of preclinical
data, plan and results of Phase I
clinical trial and plan for Phase
II clinical trial (1992). |
• |
CDRI Compound 80/53 (Anti-relapse
anti-malarial): Summary of preclinical
data, plan and results of Phase I
clinical trial and plan for Phase
II clinical study (1992). |
• |
Picroliv (A hepatoprotective agent):
Summary of preclinical data, plan
and results of Phase I clinical study
and plan for Phase II clinical trial
(1992). |
• |
CDRI Compound 80/574 (A hypolipidaemic
agent): Summary of preclinical data,
plan and results of Phase I clinical
trial and plan for Phase II clinical
study (1992). |
• |
Chandonium Iodide (A neuromuscular
blocking agent): Summary of preclinical
data, plan and results of Phase I/II
and III clinical trial (1993). |
• |
CDRI Compound 73/602 (An anti-allergic
agent): Summary of preclinical and
plan and results of Phase I clinical
trial and plan for Phase II clinical
study (1993). |
• |
Consap (A spermicidal agent; contraceptive
cream): Summary of preclinical data,
results of Phase II clinical trial
and plan for Phase III clinical trial
(1993). |
• |
Arteether (A new blood schizontocidal
anti-malarial): Summary of preclinical,
Phase I clinical data, plan and results
of Phase II clinical studies, plan
for Phase III clinical trial (1994).
|
• |
Centpropazine (A new anti-depressant):
Summary of preclinical Phase I, II
clinical data and results of Phase
III clinical trial (1995). |
• |
CDRI Compound 81/470 (Anti-helminthic
agent) Summary of preclinical data,
plan and results of Phase I clinical
trial, plan for Phase II clinical
study (1996). |
• |
Arteether (A new blood schizontocidal
anti-malarial): Summary of preclinical,
Phase I, Phase II clinical data and
plan and results of Phase III multicentric
clinical trials. (1996) |
• |
Bacoside A&B (Memory Enhancer):
Summary of preclinical data, plan
and results of Phase I clinical trial,
plan for Phase II clinical study (1997). |
• |
CDRI Compound 80/53 (Anti-relapse
anti-malarial): Summary of preclinical,
Phase I clinical data, plan and results
of Phase II/III clinical study (1997). |
• |
Memory plus (Nootropic agent): Summary
of preclinical data and plan &
results of clinical studies (1999). |
• |
Arteether (A new blood schizontocidal
anti-malarial drug): Phase IV post
marketing surveillance data (1999). |
• |
Picroliv (Hepatoprotective agent):
Summary of preclinical, Phase I clinical
study and plan and results of Phase
II multicentric clinical trial with
plan for Phase III clinical trial
(2000). |
• |
CDRI Compound 80/574 (Hypolipidaemic
agent): Summary of preclinical &
Phase I clinical study and plan, results
of Phase II clinical trial with plan
of Phase III clinical trial (2000). |
• |
Arteether (A new blood schizontocidal
anti-malarial drug): Summary of preclinical,
Phase I, II & III clinical trials
in uncomplicated & complicated
P.falciparum malaria with plan and
results of clinical trial in pediatric
patients (2000). |
• |
Consap Cream (Contraceptive agent):
Summary of preclinical, Phase I &
Phase II study with plan and results
of Phase III multicentric trials (2001). |
• |
CDRI Product: CT-1 (Anti-hyperglycaemic
agent): Regulatory pharmacology, safety
evaluation, summary of exploratory
clinical study and protocol for Phase
I/II clinical trial in patients of
Type-2 Diabetes mellitus. (Aug. 2002). |
• |
betes mellitus patients (Aug. 2002). |
• |
CDRI PRODUCT CT-1 (Anti-hyperglycaemic
agent) Protocol for Phase II clinical
trial in patients of Type 2 Dia |
• |
CDRI PRODUCT: CDR 134-D123 (Anti-hyperglycaemic
agent) Vol. 1 - Preclinical data containing
chemical and pharmacological profiles,
results of experimental studies for
efficacy evaluation and 3 months toxicity
studies in rats & monkeys (Jan.
2003). |
• |
CDRI PRODUCT: CDR 134-D123 (Anti-hyperglycaemic
agent) Vol. 2 - Protocol for Phase
I clinical trial and case record forms
(Jan. 2003). |
• |
Comp. 97/78 (Anti-malarial agent)
Protocol for Phase I clinical trial
and case record forms (Sept. 2006). |
• |
CU-1/002 preparation for management
of hyperlipidemia - Application for
permission to undertake Phase I clinical
trial (Feb. 2007). |
| • |
CDRI PRODUCT CT-1 (Anti-hyperglycaemic
agent) - Summary of chemical pharmacological,
toxicological and clinical data (Oct.
2008). |
| • |
CDRI Comp.99/373 - Investigators
Brochure (July 2009) |
• |
CDR 134-F194 (Anti-hyperglycaemic
agent) IND application for Phase I
clinical trial (Vol. I & II) (Aug.
2007). |
• |
Comp.99/373 (Anti-osteoporotic agent)
- IND application for Phase
I clinical trial (Vol. I & II)
- Aug. 2007 |
• |
a,ß Arteether (A new blood
schizontocidal anti-malarial): Summary
of preclinical, Phase I, Phase II,
Phase III clinical trials with plan
and results of clinical trials in
pediatrics patients (March 2008) |
• |
CDR 134-D123 - Product profile
|
• |
CDR 134-F194 - Investigators
Brochure (May 2009) |
• |
CDR 134-F194 (Anti-hyperglycaemic
agent) IND application for Phase I
clinical trial (Vol. I & II) -
Modified version (Aug. 2009). |
| |
